Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum

World Journal of Gastroenterology

Volumn 22, Issue 34, 2016, Pages 7692-7707

  Lemoine, Lieselotte ^a,b   Sugarbaker, Paul ^c   Van Der Speeten, Kurt ^a,b  

^a HASSELT UNIVERSITY   (Belgium)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Cytoreductive surgery; Hyperthermic intraperitoneal preoperative chemotherapy; Pathophysiology; Peritoneal carcinomatosis; Peritoneal metastatic cascade; Peritoneum

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; SOMATOMEDIN C; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

CANCER GROWTH; CARCINOGENESIS; CARCINOMATOUS PERITONITIS; CELL TRANSPORT; HOST RESISTANCE; HUMAN; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PERITONEAL CAVITY; PERITONEUM; PRIMARY TUMOR; PROTEIN EXPRESSION; RETROPERITONEUM; REVIEW; SURGEON; TREATMENT RESPONSE; TUMOR CELL; TUMOR CELL ENTRAPMENT; TUMOR GROWTH; TUMOR INVASION; TUMOR VASCULARIZATION; CARCINOMA; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOREDUCTIVE SURGERY; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); PERITONEAL NEOPLASMS; QUALITY OF LIFE; REGIONAL PERFUSION; THERMOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL PROLIFERATION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; HUMANS; HYPERTHERMIA, INDUCED; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL NEOPLASMS; PERITONEUM; QUALITY OF LIFE;

EID: 84988566175     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i34.7692     Document Type: Review

References (182)

1. Arjona-Sánchez A, Medina-Fernández FJ, Muñoz-Casares FC, Casado-Adam A, Sánchez-Hidalgo JM, Rufián-Peña S. Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview. World J Gastrointest Oncol 2014; 6: 407-412 [PMID: 25320657 DOI: 10.4251/wjgo.v6.i10.407]
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-117 [PMID: 24639052 DOI: 10.3322/caac.21220]
3. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243: 212-222 [PMID: 16432354 DOI: 10.1097/01.sla.0000197702.46394.16]
4. Aoyagi T, Terracina KP, Raza A, Takabe K. Current treatment options for colon cancer peritoneal carcinomatosis. World J Gastroenterol 2014; 20: 12493-12500 [PMID: 25253949 DOI: 10.3748/wjg.v20.i35.12493]
5. Easson AM, Bezjak A, Ross S, Wright JG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann Surg Oncol 2007; 14: 2348-2357 [PMID: 17505860 DOI: 10.1245/s10434-007-9370-3]
6. Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O, Cotte E. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol 2014; 40: 529-535 [PMID: 24370285 DOI: 10.1016/j.ejso.2013.11.019]
7. Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol 2007; 14: 3460-3471 [PMID: 17899288 DOI: 10.1245/s10434-007-9557-7]
8. Xie T, Cho YB, Wang K, Huang D, Hong HK, Choi YL, Ko YH, Nam DH, Jin J, Yang H, Fernandez J, Deng S, Rejto PA, Lee WY, Mao M. Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics 2014; 104: 234-241 [PMID: 25066378 DOI: 10.1016/j.ygeno.2014.07.012]
9. Klaver YL, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options. World J Gastroenterol 2012; 18: 5489-5494 [PMID: 23112540 DOI: 10.3748/wjg.v18.i39.5489]
10. Pasqual EM, Bertozzi S, Bacchetti S, Londero AP, Basso SM, Santeufemia DA, Lo Re G, Lumachi F. Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery. Anticancer Res 2014; 34: 2363-2368 [PMID: 24778044]
11. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550 [PMID: 12445064 DOI: 10.1046/j.1365-2168.2002.02274.x]
12. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012; 99: 699-705 [PMID: 22287157 DOI: 10.1002/bjs.8679]
13. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008; 19: 734-738 [PMID: 18272912 DOI: 10.1093/annonc/mdm607]
14. Franko JSQ, Meyers JP, Helnemann V, Falcone A, Tebbutt NC, Maughan T, Seymour M, Saltz L, Tournigand C, Diaz-Rubio E, Sougklakos I, Chibaudel B, Moen J, De Gramont A, Adams RA, Sargent DJ, Grothey A. Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer patients treated by systemic chemotherapy: Findings from 9,265 patients in the ARCAD database. Am Soc Clin Oncol Educ Book 2016; 34 Suppl 4: abstr 656
15. Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, Verwaal VJ, Mohamed F, Mirnezami AH. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer 2014; 111: 1500-1508 [PMID: 25225906 DOI: 10.1038/bjc.2014.419]
16. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743 [PMID: 14551293 DOI: 10.1200/jco.2003.04.187]
17. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432 [PMID: 18521686 DOI: 10.1245/s10434-008-9966-2]
18. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21: 799-806 [PMID: 12610177]
19. Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Bremers AJ, de Wilt JH, Te Velde EA, Verwaal VJ. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 2013; 20: 4224-4230 [PMID: 23897008 DOI: 10.1245/s10434-013-3145-9]
20. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010; 116: 5608-5618 [PMID: 20737573 DOI: 10.1002/cncr.25356]
21. Kwakman R, de Cuba EM, de Winter JP, de Hingh IH, Delis-van Diemen PM, Tijssen M, Rooimans MA, Krijgsman O, Carvalho B, Peters GJ, Bonjer HJ, Meijer GA, Te Velde EA. Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival. Br J Cancer 2015; 112: 851-856 [PMID: 25668003 DOI: 10.1038/bjc.2015.18]
22. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg 1999; 384: 576-587 [PMID: 10654274]
23. LaRocca CJ, Tuttle TM. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal cancer: choosing the right candidates. Expert Rev Anticancer Ther 2015; 15: 859-861 [PMID: 26204905 DOI: 10.1586/14737140.2015.1069187]
24. van der Wal JB, Jeekel J. Biology of the peritoneum in normal homeostasis and after surgical trauma. Colorectal Dis 2007; 9 Suppl 2: 9-13 [PMID: 17824965 DOI: 10.1111/j.1463-1318.2007.01345.x]
25. Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol 2007; 95: 93-96 [PMID: 17262739 DOI: 10.1002/jso.20676]
26. Tsilibary EC, Wissig SL. Absorption from the peritoneal cavity: SEM study of the mesothelium covering the peritoneal surface of the muscular portion of the diaphragm. Am J Anat 1977; 149: 127-133 [PMID: 67801 DOI: 10.1002/aja.1001490111]
27. Mironov VA, Gusev SA, Baradi AF. Mesothelial stomata overlying omental milky spots: scanning electron microscopic study. Cell Tissue Res 1979; 201: 327-330 [PMID: 315819]
28. Michailova K, Wassilev W, Wedel T. Scanning and transmission electron microscopic study of visceral and parietal peritoneal regions in the rat. Ann Anat 1999; 181: 253-260 [PMID: 10363107 DOI: 10.1016/S0940-9602(99)80040-5]
29. Mutsaers SE, Wilkosz S. Structure and function of mesothelial cells. Cancer Treat Res 2007; 134: 1-19 [PMID: 17633044]
30. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif 1989; 7: 74-85 [PMID: 2663038]
31. Mutsaers SE, Whitaker D, Papadimitriou JM. Changes in the concentration of microvilli on the free surface of healing mesothelium are associated with alterations in surface membrane charge. J Pathol 1996; 180: 333-339 [PMID: 8958814 DOI: 10.1002/(SICI)1096-9896(199611)180:3<333::AID-PATH659>3.0.CO;2-Y]
32. Bird SD. Mesothelial primary cilia of peritoneal and other serosal surfaces. Cell Biol Int 2004; 28: 151-159 [PMID: 14984761 DOI: 10.1016/j.cellbi.2003.11.010]
33. Fedorko ME, Hirsch JG, Fried B. Studies on transport of macromolecules and small particles across mesothelial cells of the mouse omentum. II. Kinetic features and metabolic requirements. Exp Cell Res 1971; 69: 313-323 [PMID: 5163630]
34. Wang NS. The regional difference of pleural mesothelial cells in rabbits. Am Rev Respir Dis 1974; 110: 623-633 [PMID: 4139918]
35. Dobbie JW, Pavlina T, Lloyd J, Johnson RC. Phosphatidylcholine synthesis by peritoneal mesothelium: its implications for peritoneal dialysis. Am J Kidney Dis 1988; 12: 31-36 [PMID: 3389351]
36. Topley N. The host's initial response to peritoneal infection: the pivotal role of the mesothelial cell. Perit Dial Int 1995; 15: 116-117 [PMID: 7612730]
37. Heldin P, Pertoft H. Synthesis and assembly of the hyaluronancontaining coats around normal human mesothelial cells. Exp Cell Res 1993; 208: 422-429 [PMID: 8375471 DOI: 10.1006/excr.1993.1264]
38. Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 1997; 29: 5-17 [PMID: 9076937]
39. Warn R, Harvey P, Warn A, Foley-Comer A, Heldin P, Versnel M, Arakaki N, Daikuhara Y, Laurent GJ, Herrick SE, Mutsaers SE. HGF/SF induces mesothelial cell migration and proliferation by autocrine and paracrine pathways. Exp Cell Res 2001; 267: 258-266 [PMID: 11426944 DOI: 10.1006/excr.2001.5240]
40. Wasnik AP, Maturen KE, Kaza RK, Al-Hawary MM, Francis IR. Primary and secondary disease of the peritoneum and mesentery: review of anatomy and imaging features. Abdom Imaging 2015; 40: 626-642 [PMID: 25189130 DOI: 10.1007/s00261-014-0232-8]
41. Jayne D. Molecular biology of peritoneal carcinomatosis. Cancer Treat Res 2007; 134: 21-33 [PMID: 17633045]
42. Koppe MJ, Nagtegaal ID, de Wilt JH, Ceelen WP. Recent insights into the pathophysiology of omental metastases. J Surg Oncol 2014; 110: 670-675 [PMID: 24962271 DOI: 10.1002/jso.23681]
43. Keshava A, Chapuis PH, Chan C, Lin BP, Bokey EL, Dent OF. The significance of involvement of a free serosal surface for recurrence and survival following resection of clinicopathological stage B and C rectal cancer. Colorectal Dis 2007; 9: 609-618 [PMID: 17824978 DOI: 10.1111/j.1463-1318.2006.01136.x]
44. Stewart CJ, Morris M, de Boer B, Iacopetta B. Identification of serosal invasion and extramural venous invasion on review of Dukes' stage B colonic carcinomas and correlation with survival. Histopathology 2007; 51: 372-378 [PMID: 17727478 DOI: 10.1111/j.1365-2559.2007.02787.x]
45. Honoré C, Goéré D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol 2013; 20: 183-192 [PMID: 23090572 DOI: 10.1245/s10434-012-2473-5]
46. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998; 153: 333-339 [PMID: 9708792 DOI: 10.1016/S0002-9440(10)65575-7]
47. Bracke ME. Role of adhesion molecules in locoregional cancer spread. Cancer Treat Res 2007; 134: 35-49 [PMID: 17633046]
48. Cavallaro U, Liebner S, Dejana E. Endothelial cadherins and tumor angiogenesis. Exp Cell Res 2006; 312: 659-667 [PMID: 16256984 DOI: 10.1016/j.yexcr.2005.09.019]
49. Bodenstine TM, Welch DR. Metastasis suppressors and the tumor microenvironment. Cancer Microenviron 2008; 1: 1-11 [PMID: 19308680 DOI: 10.1007/s12307-008-0001-8]
50. Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 1993; 142: 981-986 [PMID: 7682766]
51. Pocard M, Debruyne P, Bras-Gonçalves R, Mareel M, Dutrillaux B, Poupon MF. Single alteration of p53 or E-cadherin genes can alter the surgical resection benefit in an experimental model of colon cancer. Dis Colon Rectum 2001; 44: 1106-1112 [PMID: 11535849]
52. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, Kodama T, Aburatani H. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 2001; 61: 889-895 [PMID: 11221876]
53. Yonemura Y, Nojima N, Kaji M, Fujimura T, Itoh H, Ninomiya I, Miyazaki I, Endo Y, Sasaki T. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 1995; 76: 941-953 [PMID: 8625219]
54. Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 1994; 58: 393-399 [PMID: 7519585]
55. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B. Snail, Slug, and Smadinteracting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005; 103: 1631-1643 [PMID: 15742334 DOI: 10.1002/cncr.20946]
56. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28: 15-33 [PMID: 19169796 DOI: 10.1007/s10555-008-9169-0]
57. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179: 56-65 [PMID: 15942193 DOI: 10.1159/000084509]
58. Gargalionis AN, Korkolopoulou P, Farmaki E, Piperi C, Dalagiorgou G, Adamopoulos C, Levidou G, Saetta A, Fragkou P, Tsioli P, Kiaris H, Zizi-Serbetzoglou A, Karavokyros I, Papavassiliou KA, Tsavaris N, Patsouris E, Basdra EK, Papavassiliou AG. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. Int J Cancer 2015; 136: 1515-1527 [PMID: 25123959 DOI: 10.1002/ijc.29140]
59. Ibraghimov-Beskrovnaya O, Natoli TA. mTOR signaling in polycystic kidney disease. Trends Mol Med 2011; 17: 625-633 [PMID: 21775207 DOI: 10.1016/j.molmed.2011.06.003]
60. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994; 78: 725 [PMID: 8069919]
61. Nims N, Vassmer D, Maser RL. Transmembrane domain analysis of polycystin-1, the product of the polycystic kidney disease-1 (PKD1) gene: evidence for 11 membrane-spanning domains. Biochemistry 2003; 42: 13035-13048 [PMID: 14596619 DOI: 10.1021/bi035074c]
62. Dalagiorgou G, Basdra EK, Papavassiliou AG. Polycystin-1: function as a mechanosensor. Int J Biochem Cell Biol 2010; 42: 1610-1613 [PMID: 20601082 DOI: 10.1016/j.biocel.2010.06.017]
63. Parnell SC, Magenheimer BS, Maser RL, Rankin CA, Smine A, Okamoto T, Calvet JP. The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric G-proteins in vitro. Biochem Biophys Res Commun 1998; 251: 625-631 [PMID: 9792824 DOI: 10.1006/bbrc.1998.9514]
64. Hoffmeister H, Gallagher AR, Rascle A, Witzgall R. The human polycystin-2 protein represents an integral membrane protein with six membrane-spanning domains and intracellular N-and C-termini. Biochem J 2011; 433: 285-294 [PMID: 21044049 DOI: 10.1042/BJ20101141]
65. Köttgen M, Walz G. Subcellular localization and trafficking of polycystins. Pflugers Arch 2005; 451: 286-293 [PMID: 15895248 DOI: 10.1007/s00424-005-1417-3]
66. Scheffers MS, Le H, van der Bent P, Leonhard W, Prins F, Spruit L, Breuning MH, de Heer E, Peters DJ. Distinct subcellular expression of endogenous polycystin-2 in the plasma membrane and Golgi apparatus of MDCK cells. Hum Mol Genet 2002; 11: 59-67 [PMID: 11772999]
67. Koulen P, Cai Y, Geng L, Maeda Y, Nishimura S, Witzgall R, Ehrlich BE, Somlo S. Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 2002; 4: 191-197 [PMID: 11854751 DOI: 10.1038/ncb754]
68. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, Sukhatme VP, Guggino WB, Germino GG. Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents. Nature 2000; 408: 990-994 [PMID: 11140688 DOI: 10.1038/35050128]
69. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002; 13: 2508-2516 [PMID: 12239239]
70. Hayashi K, Jiang P, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM. Real-time imaging of tumor-cell shedding and trafficking in lymphatic channels. Cancer Res 2007; 67: 8223-8228 [PMID: 17804736 DOI: 10.1158/0008-5472.CAN-07-1237]
71. Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release 2015; 201: 78-89 [PMID: 25526702 DOI: 10.1016/j.jconrel.2014.12.018]
72. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg 1995; 130: 387-393 [PMID: 7710337]
73. Kristensen AT, Wiig JN, Larsen SG, Giercksky KE, Ekstrøm PO. Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer? BMC Cancer 2008; 8: 213 [PMID: 18655729 DOI: 10.1186/1471-2407-8-213]
74. Nishikawa T, Watanabe T, Sunami E, Tsuno NH, Kitayama J, Nagawa H. Prognostic value of peritoneal cytology and the combination of peritoneal cytology and peritoneal dissemination in colorectal cancer. Dis Colon Rectum 2009; 52: 2016-2021 [PMID: 19934924 DOI: 10.1007/DCR.0b013e3181b4c46e]
75. Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res 2006; 12: 417-423 [PMID: 16428481 DOI: 10.1158/1078-0432.CCR-05-1473]
76. Bae SJ, Shin US, Ki YJ, Cho SS, Moon SM, Park SH. Role of peritoneal lavage cytology and prediction of prognosis and peritoneal recurrence after curative surgery for colorectal cancer. Ann Coloproctol 2014; 30: 266-273 [PMID: 25580413 DOI: 10.3393/ac.2014.30.6.266]
77. Noura S, Ohue M, Seki Y, Yano M, Ishikawa O, Kameyama M. Long-term prognostic value of conventional peritoneal lavage cytology in patients undergoing curative colorectal cancer resection. Dis Colon Rectum 2009; 52: 1312-1320 [PMID: 19571710 DOI: 10.1007/DCR.0b013e3181a745a4]
78. Rossi Del Monte S, Ranieri D, Mazzetta F, Kazemi Nava A, Raffa S, Torrisi MR, Ziparo V. Free peritoneal tumor cells detection in gastric and colorectal cancer patients. J Surg Oncol 2012; 106: 17-23 [PMID: 22258756 DOI: 10.1002/jso.23052]
79. Altomare DF, Tedeschi M, Rotelli MT, Bocale D, Piscitelli D, Rinaldi M. Lack of prognostic role of pre-and postoperative peritoneal cytology and cytokeratin PCR-expression on local recurrence after curative anterior resection for mid-low rectal cancer. Updates Surg 2011; 63: 109-113 [PMID: 21509696 DOI: 10.1007/s13304-011-0071-x]
80. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res 1996; 82: 79-100 [PMID: 8849945]
81. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003; 22: 465-472 [PMID: 12884919]
82. Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol 2014; 25: 651-657 [PMID: 24504447 DOI: 10.1093/annonc/mdt591]
83. Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessandroni P, Giustini L, Silva RR, Falcone A, D'Emidio S, Fedeli SL. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with firstline oxaliplatin-and/or irinotecan-based chemotherapy. Br J Cancer 2009; 100: 881-887 [PMID: 19259089 DOI: 10.1038/sj.bjc.6604955]
84. Lindberg U, Karlsson R, Lassing I, Schutt CE, Höglund AS. The microfilament system and malignancy. Semin Cancer Biol 2008; 18: 2-11 [PMID: 18024149 DOI: 10.1016/j.semcancer.2007.10.002]
85. Jonji? N, Peri G, Bernasconi S, Sciacca FL, Colotta F, Pelicci P, Lanfrancone L, Mantovani A. Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 1992; 176: 1165-1174 [PMID: 1383376]
86. Klein CL, Bittinger F, Skarke CC, Wagner M, Köhler H, Walgenbach S, Kirkpatrick CJ. Effects of cytokines on the expression of cell adhesion molecules by cultured human omental mesothelial cells. Pathobiology 1995; 63: 204-212 [PMID: 8866792]
87. Müller J, Yoshida T. Interaction of murine peritoneal leukocytes and mesothelial cells: in vitro model system to survey cellular events on serosal membranes during inflammation. Clin Immunol Immunopathol 1995; 75: 231-238 [PMID: 7768040]
88. Alkhamesi NA, Ziprin P, Pfistermuller K, Peck DH, Darzi AW. ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis 2005; 22: 449-459 [PMID: 16320108 DOI: 10.1007/s10585-005-2893-8]
89. Ksiazek K, Miku?a-Pietrasik J, Catar R, Dworacki G, Winckiewicz M, Frydrychowicz M, Dragun D, Staniszewski R, Jörres A, Witowski J. Oxidative stress-dependent increase in ICAM-1 expression promotes adhesion of colorectal and pancreatic cancers to the senescent peritoneal mesothelium. Int J Cancer 2010; 127: 293-303 [PMID: 19904754 DOI: 10.1002/ijc.25036]
90. Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 2009; 69: 1469-1476 [PMID: 19208843 DOI: 10.1158/0008-5472.CAN-08-2678]
91. van Grevenstein WM, Hofland LJ, Jeekel J, van Eijck CH. The expression of adhesion molecules and the influence of inflammatory cytokines on the adhesion of human pancreatic carcinoma cells to mesothelial monolayers. Pancreas 2006; 32: 396-402 [PMID: 16670622 DOI: 10.1097/01.mpa.0000220865.80034.2a]
92. van Rossen ME, Hofland LJ, van den Tol MP, van Koetsveld PM, Jeekel J, Marquet RL, van Eijck CH. Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the peritoneum. J Pathol 2001; 193: 530-537 [PMID: 11276014 DOI: 10. 1002/1096-9896(2000)9999:9999<::AID-PATH805>3.0.CO;2-O]
93. Ziprin P, Ridgway PF, Pfistermüller KL, Peck DH, Darzi AW. ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes 2003; 10: 141-154 [PMID: 14668061]
94. Jayne DG, O'Leary R, Gill A, Hick A, Guillou PJ. A threedimensional in-vitro model for the study of peritoneal tumour metastasis. Clin Exp Metastasis 1999; 17: 515-523 [PMID: 10763918]
95. Takatsuki H, Komatsu S, Sano R, Takada Y, Tsuji T. Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). Cancer Res 2004; 64: 6065-6070 [PMID: 15342388 DOI: 10.1158/0008-5472.CAN-04-0321]
96. van Grevenstein WM, Hofland LJ, van Rossen ME, van Koetsveld PM, Jeekel J, van Eijck CH. Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers. Dig Dis Sci 2007; 52: 2775-2783 [PMID: 17394066 DOI: 10.1007/s10620-007-9778-4]
97. Yonemura Y, Endou Y, Nojima M, Kawamura T, Fujita H, Kaji M, Ajisaka H, Bandou E, Sasaki T, Yamaguchi T, Harada S, Yamamoto H. A possible role of cytokines in the formation of peritoneal dissemination. Int J Oncol 1997; 11: 349-358 [PMID: 21528221]
98. Ziprin P, Alkhamesi NA, Ridgway PF, Peck DH, Darzi AW. Tumour-expressed CD43 (sialophorin) mediates tumourmesothelial cell adhesion. Biol Chem 2004; 385: 755-761 [PMID: 15449712 DOI: 10.1515/BC.2004.092]
99. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, Matsuno S. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 2001; 91: 67-75 [PMID: 11149422]
100. Li CZ, Liu B, Wen ZQ, Li HY. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol (Praha) 2008; 54: 180-186 [PMID: 19393131]
101. Ween MP, Oehler MK, Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011; 12: 1009-1029 [PMID: 21541039 DOI: 10.3390/ijms12021009]
102. Fujisaki T, Tanaka Y, Fujii K, Mine S, Saito K, Yamada S, Yamashita U, Irimura T, Eto S. CD44 stimulation induces integrinmediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins. Cancer Res 1999; 59: 4427-4434 [PMID: 10485493]
103. Zhao LH, Lin QL, Wei J, Huai YL, Wang KJ, Yan HY. CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Pathol 2015; 8: 692-701 [PMID: 25755763]
104. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-12164 [PMID: 1465456]
105. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 4754-4756 [PMID: 7691404]
106. Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y, Baba H. CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep 2013; 29: 1570-1578 [PMID: 23404221 DOI: 10.3892/or.2013.2273]
107. Wang ZB, Li M, Li JC. Recent advances in the research of lymphatic stomata. Anat Rec (Hoboken) 2010; 293: 754-761 [PMID: 20186966 DOI: 10.1002/ar.21101]
108. Krist LF, Eestermans IL, Steenbergen JJ, Hoefsmit EC, Cuesta MA, Meyer S, Beelen RH. Cellular composition of milky spots in the human greater omentum: an immunochemical and ultrastructural study. Anat Rec 1995; 241: 163-174 [PMID: 7710133 DOI: 10.1002/ar.1092410204]
109. Shimotsuma M, Shields JW, Simpson-Morgan MW, Sakuyama A, Shirasu M, Hagiwara A, Takahashi T. Morpho-physiological function and role of omental milky spots as omentum-associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology 1993; 26: 90-101 [PMID: 8355522]
110. Cao L, Hu X, Zhang Y, Sun XT. Omental milky spots in screening gastric cancer stem cells. Neoplasma 2011; 58: 20-26 [PMID: 21067262]
111. Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006; 169: 1739-1752 [PMID: 17071597 DOI: 10.2353/ajpath.2006.051222]
112. Lopes Cardozo AM, Gupta A, Koppe MJ, Meijer S, van Leeuwen PA, Beelen RJ, Bleichrodt RP. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol 2001; 27: 359-363 [PMID: 11417980 DOI: 10.1053/ejso.2001.1117]
113. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-325 [PMID: 12884908]
114. Gentile A, D'Alessandro L, Lazzari L, Martinoglio B, Bertotti A, Mira A, Lanzetti L, Comoglio PM, Medico E. Met-driven invasive growth involves transcriptional regulation of Arhgap12. Oncogene 2008; 27: 5590-5598 [PMID: 18504429 DOI: 10.1038/onc.2008.173]
115. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6: 637-645 [PMID: 16862193 DOI: 10.1038/nrc1912]
116. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007; 67: 1670-1679 [PMID: 17308108 DOI: 10.1158/0008-5472. CAN-06-1147]
117. Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology 2010; 57: 76-80 [PMID: 20422876]
118. Akedo H, Shinkai K, Mukai M, Mori Y, Tateishi R, Tanaka K, Yamamoto R, Morishita T. Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: a model for tumor invasion. Cancer Res 1986; 46: 2416-2422 [PMID: 3697985]
119. Heath RM, Jayne DG, O'Leary R, Morrison EE, Guillou PJ. Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer 2004; 90: 1437-1442 [PMID: 15054468 DOI: 10.1038/sj.bjc.6601635]
120. Yonemura Y, Endou Y, Yamaguchi T, Nojima N, Kawamura T, Fujimura T, Obata T, Kim B, Miyazaki I, Sasaki T. Roles of VLA-2 and VLA-3 on the formation of peritoneal dissemination in gastric cancer. Int J Oncol 1996; 8: 925-931 [PMID: 21544447]
121. Kataoka H, Tanaka H, Nagaike K, Uchiyama S, Itoh H. Role of cancer cell-stroma interaction in invasive growth of cancer cells. Hum Cell 2003; 16: 1-14 [PMID: 12971620]
122. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3: 207-214 [PMID: 11994741 DOI: 10.1038/nrm763]
123. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573 [PMID: 16405877 DOI: 10.1016/j.cardiores.2005.12.002]
124. Yonemura Y, Endo Y, Yamaguchi T, Fujimura T, Obata T, Kawamura T, Nojima N, Miyazaki I, Sasaki T. Mechanisms of the formation of the peritoneal dissemination in gastric cancer. Int J Oncol 1996; 8: 795-802 [PMID: 21544429]
125. Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Gascón P, Castellví-Bel S, Maurel J. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biol 2011; 32: 417-424 [PMID: 21104178 DOI: 10.1007/s13277-010-0136-3]
126. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kössi J, Hirsimäki P, Rahkonen O, Laato M. Prognostic significance of matrix metalloproteinases-1,-2,-7 and-13 and tissue inhibitors of metalloproteinases-1,-2,-3 and-4 in colorectal cancer. Int J Cancer 2007; 121: 714-723 [PMID: 17455256 DOI: 10.1002/ijc.22747]
127. Koskensalo S, Louhimo J, Nordling S, Hagström J, Haglund C. MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol 2011; 32: 259-264 [PMID: 21207220 DOI: 10.1007/s13277-010-0080-2]
128. Ring P, Johansson K, Höyhtyä M, Rubin K, Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br J Cancer 1997; 76: 805-811 [PMID: 9310250]
129. Tahara K, Mimori K, Iinuma H, Iwatsuki M, Yokobori T, Ishii H, Anai H, Kitano S, Mori M. Serum matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer. Ann Surg Oncol 2010; 17: 3362-3369 [PMID: 20617463 DOI: 10.1245/s10434-010-1149-2]
130. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461-462 [PMID: 8597958]
131. Sunami E, Tsuno N, Osada T, Saito S, Kitayama J, Tomozawa S, Tsuruo T, Shibata Y, Muto T, Nagawa H. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000; 5: 108-114 [PMID: 10794801]
132. Sun Y, Wenger L, Brinckerhoff CE, Misra RR, Cheung HS. Basic calcium phosphate crystals induce matrix metalloproteinase-1 through the Ras/mitogen-activated protein kinase/c-Fos/AP-1/metalloproteinase 1 pathway. Involvement of transcription factor binding sites AP-1 and PEA-3. J Biol Chem 2002; 277: 1544-1552 [PMID: 11682465 DOI: 10.1074/jbc.M100567200]
133. Hettiaratchi A, Hawkins NJ, McKenzie G, Ward RL, Hunt JE, Wakefield D, Di Girolamo N. The collagenase-1 (MMP-1) gene promoter polymorphism-1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer 2007; 96: 783-792 [PMID: 17311017 DOI: 10.1038/sj.bjc.6603630]
134. Groblewska M, Mroczko B, Gryko M, Pryczynicz A, Guzi?ska-Ustymowicz K, K?dra B, Kemona A, Szmitkowski M. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients. Tumour Biol 2014; 35: 3793-3802 [PMID: 24395652 DOI: 10.1007/s13277-013-1502-8]
135. Li CY, Yuan P, Lin SS, Song CF, Guan WY, Yuan L, Lai RB, Gao Y, Wang Y. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumour Biol 2013; 34: 735-741 [PMID: 23269605 DOI: 10.1007/s13277-012-0601-2]
136. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Danø K, Nielsen BS. MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 2006; 4: 293-302 [PMID: 16687484 DOI: 10.1158/1541-7786.MCR-06-0003]
137. Alkhamesi NA, Roberts G, Ziprin P, Peck DH. Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction. Biomark Insights 2007; 2: 377-384 [PMID: 19662219]
138. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006; 231: 20-27 [PMID: 16380641]
139. Yamada T, Oshima T, Yoshihara K, Tamura S, Kanazawa A, Inagaki D, Yamamoto N, Sato T, Fujii S, Numata K, Kunisaki C, Shiozawa M, Morinaga S, Akaike M, Rino Y, Tanaka K, Masuda M, Imada T. Overexpression of MMP-13 gene in colorectal cancer with liver metastasis. Anticancer Res 2010; 30: 2693-2699 [PMID: 20683000]
140. Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, Hwang BD, Yoon WH. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006; 6: 211 [PMID: 16916471 DOI: 10.1186/1471-2407-6-211]
141. Klinge U, Rosch R, Junge K, Krones CJ, Stumpf M, Lynen-Jansen P, Mertens PR, Schumpelick V. Different matrix micro-environments in colon cancer and diverticular disease. Int J Colorectal Dis 2007; 22: 515-520 [PMID: 17021746 DOI: 10.1007/s00384-006-0199-1]
142. Fujii T, Obara T, Tanno S, Ura H, Kohgo Y. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology 1999; 46: 2299-2308 [PMID: 10521987]
143. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82: 184-193 [PMID: 12619063 DOI: 10.1002/jso.10210]
144. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-337 [PMID: 15549095 DOI: 10.1038/nature03096]
145. Davies DE, Farmer S, White J, Senior PV, Warnes SL, Alexander P. Contribution of host-derived growth factors to in vivo growth of a transplantable murine mammary carcinoma. Br J Cancer 1994; 70: 263-269 [PMID: 8054274]
146. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-26 [PMID: 15142631 DOI: 10.1016/j.ijrobp.2003.11.041]
147. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29: 3-14 [PMID: 11894009]
148. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232 [PMID: 7612182]
149. Yonemura Y, Sugiyama K, Fushida S, Kamata T, Ohoyama S, Kimura H, Yamaguchi A, Miyazaki I. Tissue status of epidermal growth factor and its receptor as an indicator of poor prognosis in patients with gastric cancer. Anal Cell Pathol 1991; 3: 343-350 [PMID: 1751401]
150. Ziober BL, Willson JK, Hymphrey LE, Childress-Fields K, Brattain MG. Autocrine transforming growth factor-alpha is associated with progression of transformed properties in human colon cancer cells. J Biol Chem 1993; 268: 691-698 [PMID: 8416972]
151. Awwad RA, Sergina N, Yang H, Ziober B, Willson JK, Zborowska E, Humphrey LE, Fan R, Ko TC, Brattain MG, Howell GM. The role of transforming growth factor alpha in determining growth factor independence. Cancer Res 2003; 63: 4731-4738 [PMID: 12907656]
152. Tampellini M, Longo M, Cappia S, Bacillo E, Alabiso I, Volante M, Dogliotti L, Papotti M. Co-expression of EGF receptor, TGFalpha and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. Virchows Arch 2007; 450: 321-328 [PMID: 17265080 DOI: 10.1007/s00428-007-0370-2]
153. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163 [PMID: 7540132 DOI: 10.1210/edrv-16-2-143]
154. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 2008; 14: 8263-8269 [PMID: 19073970 DOI: 10.1158/1078-0432. CCR-08-0480]
155. Olcina MM, Leszczynska KB, Senra JM, Isa NF, Harada H, Hammond EM. H3K9me3 facilitates hypoxia-induced p53-dependent apoptosis through repression of APAK. Oncogene 2016; 35: 793-799 [PMID: 25961932 DOI: 10.1038/onc.2015.134]
156. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res 1996; 82: 53-63 [PMID: 8849943]
157. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
158. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005; 105: 659-669 [PMID: 15374877 DOI: 10.1182/blood-2004-07-2958]
159. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732 [PMID: 13130303 DOI: 10.1038/nrc1187]
160. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996; 271: C1172-C1180 [PMID: 8897823]
161. Greijer AE, Delis-van Diemen PM, Fijneman RJ, Giles RH, Voest EE, van Hinsbergh VW, Meijer GA. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch 2008; 452: 535-544 [PMID: 18351386 DOI: 10.1007/s00428-008-0578-9]
162. Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L, Zhang Y. Clinicopathologic significance of HIF-1?, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol 2010; 2010: [PMID: 20953377 DOI: 10.1155/2010/537531]
163. Rosa M, Abdelbaqi M, Bui KM, Nasir A, Bui MM, Shibata D, Coppola D. Overexpression of Vascular Endothelial Growth Factor A in Invasive Micropapillary Colorectal Carcinoma. Cancer Control 2015; 22: 206-210 [PMID: 26068766]
164. Yang X, Zhang Y, Hosaka K, Andersson P, Wang J, Tholander F, Cao Z, Morikawa H, Tegnér J, Yang Y, Iwamoto H, Lim S, Cao Y. VEGF-B promotes cancer metastasis through a VEGFA-independent mechanism and serves as a marker of poor prognosis for cancer patients. Proc Natl Acad Sci USA 2015; 112: E2900-E2909 [PMID: 25991856 DOI: 10.1073/pnas.1503500112]
165. Chen H, Guan R, Lei Y, Chen J, Ge Q, Zhang X, Dou R, Chen H, Liu H, Qi X, Zhou X, Chen C. Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. BMC Cancer 2015; 15: 103 [PMID: 25884175 DOI: 10.1186/s12885-015-1109-0]
166. Funaki H, Nishimura G, Harada S, Ninomiya I, Terada I, Fushida S, Tani T, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K. Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma. Oncology 2003; 64: 416-422 [PMID: 12759540]
167. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703 [PMID: 17719546 DOI: 10.1016/j.cell.2007.06.054]
168. De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med 2002; 12: 241-246 [PMID: 12242046]
169. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845 [PMID: 1279431 DOI: 10.1038/359843a0]
170. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, Drazan KE, Bucana CD, Hicklin DJ, Ellis LM. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001; 85: 584-589 [PMID: 11506500 DOI: 10.1054/bjoc.2001.1936]
171. Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008; 15: 738-744 [PMID: 18043973 DOI: 10.1245/s10434-007-9699-7]
172. Zeamari S, Roos E, Stewart FA. Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue. Eur J Cancer 2004; 40: 1431-1440 [PMID: 15177504 DOI: 10.1016/j.ejca.2004.01.035]
173. Sugarbaker PH. A perspective on clinical research strategies in carcinoma of the large bowel. World J Surg 1991; 15: 609-616 [PMID: 1949860]
174. van den Tol PM, van Rossen EE, van Eijck CH, Bonthuis F, Marquet RL, Jeekel H. Reduction of peritoneal trauma by using nonsurgical gauze leads to less implantation metastasis of spilled tumor cells. Ann Surg 1998; 227: 242-248 [PMID: 9488523]
175. Lee IK, Vansaun MN, Shim JH, Matrisian LM, Gorden DL. Increased metastases are associated with inflammation and matrix metalloproteinase-9 activity at incision sites in a murine model of peritoneal dissemination of colorectal cancer. J Surg Res 2013; 180: 252-259 [PMID: 22763216 DOI: 10.1016/j.jss.2012.04.074]
176. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 69-89 [PMID: 15588763 DOI: 10.1016/j.bbcan.2004.09.006]
177. Savalgi RS. Port-site metastasis in the abdominal wall: fact or fiction? Semin Surg Oncol 1998; 15: 189-193 [PMID: 9779631]
178. Ouellette JR, Ko AS, Lefor AT. The physiologic effects of laparoscopy: applications in oncology. Cancer J 2005; 11: 2-9 [PMID: 15831218]
179. Steinert R, Lippert H, Reymond MA. Tumor cell dissemination during laparoscopy: prevention and therapeutic opportunities. Dig Surg 2002; 19: 464-472 [PMID: 12499738]
180. Jingli C, Rong C, Rubai X. Influence of colorectal laparoscopic surgery on dissemination and seeding of tumor cells. Surg Endosc 2006; 20: 1759-1761 [PMID: 17024537 DOI: 10.1007/s00464-005-0694-4]
181. Paraskeva PA, Ridgway PF, Jones T, Smith A, Peck DH, Darzi AW. Laparoscopic environmental changes during surgery enhance the invasive potential of tumours. Tumour Biol 2005; 26: 94-102 [PMID: 15897689 DOI: 10.1159/000085816]
182. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68 [PMID: 19917863 DOI: 10.1200/JCO.2009.23.9285]